Related Experiment Video
Updated: Jun 23, 2026
05:42
Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum
J Sarris1, D J Kavanagh, J Adams
1School of Medicine, University of Queensland, Australia. j.sarris@uq.edu.au
Complementary Therapies in Medicine
|April 29, 2009
Summary
This study investigates the anxiety and depression treatment potential of a kava extract in a clinical trial. Findings could support kava
Area of Science:
- Pharmacology and Psychiatry
- Clinical Trial Design
- Herbal Medicine Research
Background:
- Piper methysticum (kava) has traditional uses for anxiety.
- Limited high-quality clinical data exists for standardized kava extracts.
- Anxiety and depression spectrum disorders affect a significant population.
Purpose of the Study:
- To evaluate the anxiolytic and thymoleptic efficacy of an aqueous kava extract.
- To assess kava's impact on varying levels of depressive symptoms.
- To explore participant experiences with kava through qualitative methods.
Main Methods:
- The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week, placebo-controlled, double-blind, cross-over trial.
- 60 adult participants (18-65) with anxiety and depressive symptoms were enrolled.
- Standardized aqueous mono-extract of Piper methysticum (kava) was administered.
Main Results:
- Preliminary safety assessment of the aqueous kava extract in humans.
- Data on the anxiolytic and thymoleptic effects of kava.
- Insights into participant experiences with kava treatment.
Conclusions:
- Positive results may support the re-introduction of kava in Western markets.
- An effective and safe kava extract could benefit patients with anxiety disorders.
- Socioeconomic benefits for Pacific Island nations are a potential outcome.
